FREDERICK, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...
Factorial’s high-power, lightweight, solid-state batteries have demonstrated real-world performance, including over 1,200 km (745 miles) of driving range in vehicle testing and are being advanced ...
Abstract: Analytical expressions that have been derived to calculate ac resistance and losses of magnetic devices at high frequencies have primarily used a one-dimensional approximation, and have used ...
Physics and Python stuff. Most of the videos here are either adapted from class lectures or solving physics problems. I really like to use numerical calculations without all the fancy programming ...
CGAL version, kernels: 6.0.1, Cartesian, Extended_cartesian Python Version: Python 3.13.3 OpenCSG version: OpenCSG 1.8.1 Clipper2 version: 1.5.2 Manifold version: 3.2 ...
Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...
Background: In my experience, given a customizer initialization the spinner usually increments the last digit. Eg, if testparam8=0.567; appears, the increment is 0.001. Problem: While the increment is ...
Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...
Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol Assessment ...